| Targeting the epidermal growth factor receptor with molecular degraders: State-of-the-art and future opportunities P Maity, J Chatterjee, KT Patil, S Arora, MK Katiyar, M Kumar, ... Journal of Medicinal Chemistry 66 (5), 3135-3172, 2023 | 16 | 2023 |
| Epidermal growth factor receptor and its trafficking regulation by acetylation: Implication in resistance and exploring the newer therapeutic avenues in cancer M Kumar, G Joshi, J Chatterjee, R Kumar Current Topics in Medicinal Chemistry 20 (12), 1105-1123, 2020 | 11 | 2020 |
| In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor … ZR Bhat, M Kumar, N Sharma, UP Yadav, T Singh, G Joshi, B Pujala, ... Molecules 27 (17), 5540, 2022 | 5 | 2022 |
| FDA approved five-membered ring fused pyrimidine-based derivatives and their biological properties M Kumar, J Chatterjee, D Rani, R Kumar Fused Pyrimidine-Based Drug Discovery, 117-164, 2023 | 2 | 2023 |
| Imidazo[1,2‐a]Quinoxaline‐2‐Carbonitrile Derivative (RA‐22) Inhibits Self‐Renewal and Growth of Cancer Stem and Cancer Cells via Downregulating AKT Pathway P Kumar, U Prasad Yadav, G Joshi, S Arora, M Kumar, J Chatterjee, ... ChemistrySelect 9 (23), e202400223, 2024 | | 2024 |
| Design, synthesis, and anticancer assessment of structural analogues of (E)-1-((3, 4, 5-trimethoxybenzylidene) amino)-4-(3, 4, 5-trimethoxyphenyl) imidazo [1, 2-a] quinoxaline … M Kumar, KT Patil, P Maity, J Chatterjee, T Singh, G Joshi, S Singh, ... RSC Medicinal Chemistry, 2024 | | 2024 |
Raj Kumar, FRSCProfessor of Medicinal/Pharmaceutical Chemistry, Central University of Punjab在 cup.edu.in 的电子邮件经过验证
